S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.48
+1.80
+10.79%
KPRX · Kiora Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Kiora Pharmaceuticals Inc (KPRX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$2.33
-0.23
(-8.98%)
● At close: October 20 at 4:00:00 PM EDT
DAY'S RANGE
$2.33
$2.33
$2.33
52-WEEK RANGE
$2.33
$1.76
$2.91
What's happening
- KPRX is down 8.98% today, trading at $2.33. — Live quote
- Volume today (154) is well below its 3-month average of 18,530. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.34 actual vs. $-0.63 estimated (+46.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
KPRX
+18.78%
vs S&P 500
+5.41%
1-YEAR RETURN
KPRX
-5.26%
vs S&P 500
-20.43%
6-MONTH RETURN
KPRX
-7.14%
3-MONTH RETURN
KPRX
-7.51%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.34
Est. $-0.63
BEAT +46.2%
2026-04-26 (Q1 2026)
$-0.58
Est. $-0.72
BEAT +19.9%
2026-01-26 (Q4 2025)
$-1.59
Est. $-0.68
MISS -132.7%
2025-10-26 (Q3 2025)
$0.01
Est. $-0.75
BEAT +101.3%
Valuation Measures & Ratios
Enterprise Value4$3.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.65
Price / Book70.69
EV4 / Revenue—
EV4 / EBITDA0.76
Profit Margin70.11%
Operating Margin66.65%
Return on Equity (ROE8)-63.39%
Return on Assets (ROA9)-44.34%
Avg Volume (3M)18,530
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $15.9M | $7.9M | $7.5M | $11.2M | $12.7M |
| P/E | -2.41 | -1.17 | -0.97 | -1.12 | 2.25 |
| Price/Sales | — | — | — | 558.04 | 0.79 |
| Price/Book | 0.94 | 0.57 | 0.33 | 0.50 | 0.53 |
| EV/Revenue | — | — | — | 506.63 | 0.55 |
| EV/EBITDA | -1.12 | 0.38 | -0.22 | — | — |
| ROE | -39.29% | -48.34% | -34.50% | -45.10% | 23.73% |
| ROA | -27.85% | -31.74% | -25.89% | -31.24% | 16.54% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,432
Change from Prior Settlement-14.61%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Net profit margin is 70.1%. Finnhub fundamentals ↗
Potential concerns
- Trailing 52-week price return is -5.3%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-09-17; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on KPRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 | $20.0K | $16.0M |
| Operating income | -$2.2M | -$2.5M | -$794.4K | -$2.4M | -$2.3M | -$3.6M | -$2.5M | $13.2M |
| Net income | -$2.1M | -$2.4M | $26.8K | -$2.2M | -$2.2M | -$3.4M | -$2.2M | $13.5M |
| EPS (diluted) | $-0.34 | $-0.58 | $0.01 | $-0.54 | $-0.52 | $-0.81 | $-0.53 | $3.46 |
| EPS (basic) | $-0.34 | $-0.58 | $0.01 | $-0.54 | $-0.52 | $-0.81 | $-0.53 | $4.67 |
| Operating margin | — | — | — | — | — | — | -$12.7K | $83 |
| Net margin | — | — | — | — | — | — | -$11.1K | $84 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $23.8M | $21.2M | $24.3M | $29.9M | $31.9M | $34.0M | $36.5M | $38.5M |
| Total liabilities | $6.9M | $7.3M | $8.1M | $7.5M | $9.8M | $10.3M | $10.7M | $8.5M |
| Stockholders' equity | $16.9M | $13.9M | $16.1M | $22.4M | $22.1M | $23.7M | $25.8M | $30.0M |
| Total current assets | $21.3M | $18.7M | $21.7M | $22.7M | $24.7M | $27.1M | $29.7M | $31.7M |
| Total current liabilities | $2.4M | $2.8M | $3.6M | $2.6M | $3.2M | $5.3M | $6.0M | $3.5M |
| Cash & equivalents | $7.1M | $11.0M | $8.7M | $5.5M | $1.0M | $3.8M | $3.8M | $5.6M |
| Marketable securities (current) | $9.8M | $2.9M | $8.4M | $13.9M | $19.6M | $20.3M | $23.0M | $23.4M |
| Accounts receivable | $1.1M | $1.5M | $1.5M | $1.2M | $2.4M | $1.3M | $601.2K | $1.8M |
| Property, plant & equipment | $99.6K | $86.8K | $91.7K | $101.8K | $106.8K | $5.0K | $5.2K | $62.6K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $2.1M | $2.1M | $2.1M | $6.7M | $6.7M | $6.7M | $6.7M | $6.7M |
| Other non-current assets | $85.4K | $88.2K | $59.7K | $58.1K | $61.0K | $64.3K | $24.9K | $29.9K |
| Accounts payable | $216.5K | $594.9K | $1.1M | $241.5K | $282.5K | $942.5K | $415.6K | $660.4K |
| Accrued liabilities | $2.0M | $2.0M | $2.4M | $2.2M | $2.5M | $3.5M | $4.6M | $1.7M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $281.9K | $277.6K | $275.3K | $272.0K | $272.0K | $267.7K | $267.7K | $267.7K |
| Retained earnings | -$158.7M | -$156.6M | -$154.2M | -$147.7M | -$147.7M | -$145.6M | -$143.4M | -$139.2M |
| Accumulated other comprehensive income (loss) | -$255.8K | -$228.8K | -$246.1K | -$243.7K | -$245.8K | -$297.2K | -$282.2K | -$75.2K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.9M | -$3.2M | -$2.2M | -$1.3M | -$3.8M | -$2.7M | -$2.3M | $920.1K |
| Investing cash flow | -$6.9M | $5.4M | $5.3M | $5.7M | $664.2K | $2.7M | $482.7K | -$1.9M |
| Financing cash flow | $4.9M | -$842 | $296 | $0 | $265.4K | $0 | $0 | $0 |
| Free cash flow | -$1.9M | -$3.2M | -$2.3M | -$1.3M | -$3.8M | -$2.7M | -$2.2M | $920.1K |
| Capital expenditures | $23.5K | $5.0K | $78.2K | $431 | $32.2K | $0 | -$45.0K | $0 |
| Depreciation & amortization | $10.7K | $10.6K | $10.5K | $10.6K | $3.4K | $318 | $5.9K | $2.1K |
| Share-based compensation | $109.3K | $209.5K | $234.4K | $254.4K | $262.8K | $148.6K | $160.2K | $171.2K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | -$452.9K | $21.5K | $309.5K | -$1.2M | $1.1M | $736.4K | -$1.2M | $442.2K |
| Change in accounts payable | -$378.5K | -$303.0K | $655.9K | -$40.6K | -$662.0K | $1.2M | -$224.9K | $384.6K |
| Purchases of investments | $9.1M | $0 | $0 | $0 | $4.6M | $3.6M | $6.5M | $7.8M |
| Sales/maturities of investments | $0 | $0 | $0 | $0 | $225.0K | $80.0K | $1.2M | $135.2K |
| Debt issued | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $9.3K | $1.0K | — | — | $0 | $0 | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | — | — |
| Operating income | -$12.8M | $4.5M | -$12.6M | -$12.3M | -$14.2M |
| Net income | -$10.8M | $3.6M | -$12.5M | -$13.6M | -$13.8M |
| EPS (diluted) | $-2.64 | $0.87 | $-24.25 | $-18.55 | $-57.12 |
| EPS (basic) | $-2.60 | $0.93 | $-24.25 | $-18.55 | $-57.12 |
| Operating margin | — | $28 | — | — | — |
| Net margin | — | $22 | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $24.3M | $36.5M | $13.7M | $18.7M | $20.1M |
| Total liabilities | $8.1M | $10.7M | $7.6M | $7.3M | $5.6M |
| Stockholders' equity | $16.1M | $25.8M | $6.1M | $11.4M | $14.6M |
| Total current assets | $21.7M | $29.7M | $4.7M | $7.7M | $9.0M |
| Total current liabilities | $3.6M | $6.0M | $1.6M | $3.3M | $1.6M |
| Cash & equivalents | $8.7M | $3.8M | $2.5M | $6.0M | $7.9M |
| Marketable securities (current) | $8.4M | $23.0M | $0 | — | — |
| Accounts receivable | $1.5M | $601.2K | $0 | — | — |
| Property, plant & equipment | $91.7K | $5.2K | $8.1K | $55.2K | $74.0K |
| Goodwill | — | — | — | $0 | $0 |
| Intangible assets | $2.1M | $6.7M | $8.8M | $10.7M | $10.8M |
| Other non-current assets | $59.7K | $24.9K | $40.8K | $33.0K | $43.0K |
| Accounts payable | $1.1M | $415.6K | $206.3K | $1.0M | $160.6K |
| Accrued liabilities | $2.4M | $4.6M | $1.4M | $1.8M | $1.3M |
| Deferred revenue (current) | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $275.3K | $267.7K | $77.1K | $18.0K | $3.2K |
| Retained earnings | -$154.2M | -$143.4M | -$147.0M | -$134.5M | -$120.9M |
| Accumulated other comprehensive income (loss) | -$246.1K | -$282.2K | -$182.8K | -$182.7K | -$86.4K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.0M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Investing cash flow | $14.4M | -$22.7M | $0 | $6.4K | -$157.0K |
| Financing cash flow | $265.7K | $15.5M | $6.0M | $8.6M | $17.6M |
| Free cash flow | -$10.1M | $8.6M | -$9.6M | -$10.4M | -$10.7M |
| Capital expenditures | $110.8K | $6.3K | $0 | $0 | $63.9K |
| Depreciation & amortization | $24.8K | $19.2K | $51.8K | $41.6K | $45.3K |
| Share-based compensation | $900.2K | $656.6K | $754.9K | $462.4K | $842.5K |
| Deferred income taxes | — | — | $90.3K | -$113.0K | -$192.6K |
| Change in accounts receivable | $921.6K | $601.2K | $0 | — | — |
| Change in accounts payable | $1.1M | $226.1K | -$808.0K | $782.5K | -$310.7K |
| Purchases of investments | $8.2M | $35.6M | $0 | — | — |
| Sales/maturities of investments | $305.0K | $1.3M | $0 | — | — |
| Debt issued | — | — | — | — | $0 |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding KPRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-04-01 to 2026-07-01
Recent transactions
- Most recent: Tosca Melissa (CFO) — Tax withholding of 911 shares on 2026-07-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Tosca Melissa | CFO | Tax withholding | 2026-07-01 | 911 |
| Strem Brian M. | President and CEO | Tax withholding | 2026-07-01 | 1,869 |
| Daniels Eric Joseph | Chief Development Officer | Tax withholding | 2026-04-01 | 929 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-01 | Tosca Melissa | CFO | Tax withholding | 911 | $2.66 |
| 2026-07-01 | Strem Brian M. | President and CEO | Tax withholding | 1,869 | $2.66 |
| 2026-04-01 | Tosca Melissa | CFO | Tax withholding | 929 | $1.95 |
| 2026-04-01 | Daniels Eric Joseph | Chief Development Officer | Tax withholding | 929 | $1.95 |
| 2026-04-01 | Strem Brian M. | President and CEO | Tax withholding | 1,906 | $1.95 |
| 2026-03-06 | Daniels Eric Joseph | Chief Development Officer | Grant / award | 6,533 | $0.00 |
| 2026-03-06 | Strem Brian M. | President and CEO | Grant / award | 16,733 | $0.00 |
| 2026-03-06 | Tosca Melissa | CFO | Grant / award | 6,533 | $0.00 |
| 2026-03-03 | Daniels Eric Joseph | Chief Development Officer | Tax withholding | 238 | $2.02 |
| 2026-03-03 | Strem Brian M. | President and CEO | Tax withholding | 238 | $2.02 |
| 2025-04-01 | Tosca Melissa | CFO | Grant / award | 7,772 | $0.00 |
| 2025-04-01 | Daniels Eric Joseph | Chief Development Officer | Grant / award | 7,772 | $0.00 |
| 2025-04-01 | Strem Brian M. | President and CEO | Grant / award | 15,941 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:57 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-17 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-08-19 | 8-K | 2026-08-19 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-18 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-10 | View on SEC.gov → |
Recent news
Headlines about KPRX (Kiora Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis
kalkine.ca · 2026-10-21 -
Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent Range - Ichimoku Kumo Break
www.dars.gov.et · 2026-10-21 -
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Yahoo Finance · 2026-09-08 -
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Yahoo Finance · 2026-08-19 -
Kiora Pharmaceuticals GAAP EPS of -$0.34 beats by $0.28
Seeking Alpha · 2026-08-07 -
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance · 2026-08-07 -
SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer
Yahoo Finance · 2026-07-15 -
SS Innovations names Sarah Romano as CFO
Yahoo Finance · 2026-07-15
No headlines in this category right now — try “All”.